Literature DB >> 8047747

Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research.

T R Fleming1, R L Prentice, M S Pepe, D Glidden.   

Abstract

Surrogate endpoints have been defined by Prentice as response variables that can substitute for a 'true' endpoint for the purpose of comparing specific interventions or treatments in a clinical trial. The applicability of this definition, and of related surrogate endpoint criteria, is discussed, with emphasis on cancer and AIDS research settings. Auxiliary endpoints are defined as response variables, or covariates, that can strengthen true endpoint analyses. Specifically, such response variables provide some additional information on true endpoint occurrence times for study subjects having censored values for such times. Auxiliary variables will very frequently be available, and they may be able to be used without making additional strong assumptions. Approaches to the use of auxiliary variables using ideas based on augmented score and augmented likelihood methods are described.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8047747     DOI: 10.1002/sim.4780130906

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  31 in total

Review 1.  New trial designs to assess antitumor and antiproliferative agents in prostate cancer.

Authors:  Walter Stadler
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 2.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 3.  The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests.

Authors:  Behrouz Kassaï; Nirav R Shah; Alain Leizorovicza; Michel Cucherat; Francois Gueyffier; Jean-Pierre Boissel
Journal:  J Clin Epidemiol       Date:  2005-10       Impact factor: 6.437

Review 4.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

5.  New strategies in Barrett's esophagus: integrating clonal evolutionary theory with clinical management.

Authors:  Brian J Reid; Rumen Kostadinov; Carlo C Maley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

6.  Parametric latent class joint model for a longitudinal biomarker and recurrent events.

Authors:  Jun Han; Elizabeth H Slate; Edsel A Peña
Journal:  Stat Med       Date:  2007-12-20       Impact factor: 2.373

Review 7.  The perils of surrogate endpoints.

Authors:  William S Weintraub; Thomas F Lüscher; Stuart Pocock
Journal:  Eur Heart J       Date:  2015-05-13       Impact factor: 29.983

Review 8.  Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Brian J Reid; Thomas G Paulson; Xiaohong Li
Journal:  Gastroenterology       Date:  2015-07-21       Impact factor: 22.682

9.  Nonparametric discrete survival function estimation with uncertain endpoints using an internal validation subsample.

Authors:  Jarcy Zee; Sharon X Xie
Journal:  Biometrics       Date:  2015-04-27       Impact factor: 2.571

10.  Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study.

Authors:  Dennis L Chao; Carissa A Sanchez; Patricia C Galipeau; Patricia L Blount; Thomas G Paulson; David S Cowan; Kamran Ayub; Robert D Odze; Peter S Rabinovitch; Brian J Reid
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.